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Vitamin C was first suggested to 
have cancer-fighting properties in 
the 1930s and has been the subject 
of controversy ever since. Despite re-
peated reports of selective cancer cell 
toxicity induced by high-dose vitamin 
C treatment in vitro and in mouse 
models, the mechanism of action has 
remained elusive.  
Yun et al. [1] have recently shed 
light on what was until now the elusive 
mechanism by which vitamin C (aka 
ascorbate) induces toxicity in selected 
oncogene-driven cancers. They reported 
that in cells with mutations of KRAS or 
BRAF, death is not caused by vitamin 
C itself, but rather by its oxidized form 
dehydroascorbate (DHA). Whereas 
vitamin C enters cells through sodium 
cotransporters, DHA competes with 
glucose for uptake through glucose 
transporters (particularly GLUT1 and 
GLUT4) and then is reduced back to 
vitamin C in cells [2] (Figure 1). It was 
previously observed that while mela-
noma cell lines take up DHA at much 
higher rates than vitamin C, normal 
melanocytes do not, demonstrating that 
transformation-driven upregulation of 
GLUTs leads to increased uptake of 
DHA [3]. More recently, using Mag-
netic Resonance Spectroscopy Imaging, 
it was demonstrated that hyperpolarized 
13C-labeled DHA is rapidly taken up by 
cancer cells and converted to vitamin C, 
illustrating the tumors’ reducing state 
[4]. Yun et al. [1] now show that the 
reduction of DHA back to vitamin C 
is at the crux of the vitamin C-induced 
cell death observed in these cancer cells.
Mutations in KRAS or BRAF are 
found in approximately half of the cases 
of colorectal cancer (CRC) and their 
expression correlates with an increase 
in GLUT1 expression, glucose uptake 
and reliance on glycolysis. Yun et al. 
[1] observed that vitamin C is oxidized 
to DHA in tissue culture media and that 
KRAS or BRAF mutated CRC cell lines 
take up more DHA compared to their 
wild-type counterparts. More impor-
tantly, they found that DHA induces 
death in the mutant lines, but not in 
wild-type counterparts overexpressing 
GLUT1, suggesting that additional 
oncogenic reprogramming is necessary 
for DHA-induced toxicity. The authors 
then profiled metabolic changes after 
treatment with vitamin C. In cells with 
KRAS or BRAF mutations, they found 
an accumulation of the glycolytic inter-
mediates upstream of glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) 
whereas those downstream of GAPDH 
were depleted. This indicated a decrease 
in GAPDH activity and a concomitant 
diversion of glucose into the oxida-
tive phase of the pentose phosphate 
pathway (PPP), a metabolic shift that, 
upon oxidative stress, helps restore 
NADPH levels and cellular reducing 
potential (Figure 1). Indeed, Yun and 
co-workers found that the intracellular 
reduction of DHA back to vitamin C 
depleted the cellular stores of reduced 
glutathione (GSH, the major antioxidant 
in cells), leading to an increase in reac-
tive oxygen species (ROS). Further-
more, they found that, upon exposure 
to DHA, GAPDH itself was oxidized 
(on Cys152), and consequently inhibited. 
Inhibition of GAPDH caused energy 
stress in the highly glycolytic mutant 
cell lines, leading to cell death. In mice 
harboring tumor xenografts with either 
KRAS or BRAF mutations, treatment 
with high doses of vitamin C reduced 
tumor size. Treatment also reduced 
the number and size of polyps in an 
Apc-driven transgenic mouse model 
of intestinal cancer, but again, only in 
tumors expressing mutant Kras. More-
over, in addition to showing the direct 
inhibition of GAPDH by oxidation, the 
authors demonstrated that its activity 
is further hindered by DHA-induced 
NAD+ depletion, since GAPDH activ-
ity relies on the availability of NAD+ 
as a co-substrate. The major NAD+ 
consumer, the DNA repairing enzyme 
poly ADP-ribose polymerase (PARP) 
was then investigated. It was found 
that the increase in ROS after high-dose 
vitamin C treatment also induced DNA 
damage and PARP activation in KRAS 
or BRAF transformed cells. Providing 
the cells with a PARP inhibitor or an 
NAD+ precursor partially rescued their 
viability. Thus, ROS cause the inhibi-
tion of GAPDH activity in cells on 
two fronts: first, via inducing its direct 
oxidation and second, by causing NAD+ 
depletion (Figure 1). Yun  et al. [1] thus 
demonstrated an intricate mechanism 
by which oncogenic reprogramming, 
which causes glycolysis addiction, in-
duces a metabolic vulnerability which 
can be exploited with high doses of 
DHA that elevate intracellular ROS as 
it is converted back to vitamin C. 
Despite numerous clinical studies, 
the anti-cancer property of vitamin C 
has remained controversial. Potential 
translation of the mechanism presented 
by Yun et al. [1] to therapeutic applica-
tion raises concerns regarding toxici-
ties of high-dose vitamin C treatment. 
Though the authors do not report side 
effects in their mice (treated daily with 
4-8 g/kg body weight IP), the upper 
dose equates to over half a kilogram 
for the average person. High-dose 
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oral supplementation of vitamin C 
is associated with increased kidney 
stone incidence, and clinical studies 
demonstrated significant renal, cardiac, 
and metabolic toxicity upon vitamin C 
administration. Still, overall reports of 
toxicity are variable, poorly graded, and 
therefore inconclusive [5, 6]. Affinity 
studies of DHA for GLUT1 may help 
establish a lower effective dose, though 
unwanted side effects in tissues that 
highly express GLUT1 need to be con-
sidered. The brain obtains vitamin C by 
uptake of DHA through GLUT1 at the 
blood-brain barrier and its subsequent 
reduction [7]. Erythrocytes express 
high levels of GLUT1 and are crucial 
for ascorbate recycling, keeping DHA 
levels low [8]. Importantly, erythrocytes 
rely solely on glycolysis for energy 
production. Thus, high DHA levels may 
induce brain toxicity and haemolysis via 
mechanisms similar to those described 
by Yun et al. [1].  
Though vitamin C oxidizes rapidly in 
tissue culture media, it acts mainly as an 
antioxidant in vivo. It remains unclear 
how and where circulating vitamin C is 
oxidized in vivo, an issue not addressed 
by Yun et al. [1]. Oxidation of vitamin 
C to DHA by tumor stroma has been 
suggested [9], complicating the abil-
ity to predict tumor responsiveness to 
the treatment. As such, without being 
able to control the extent of vitamin C 
oxidation to DHA, effectiveness and 
toxicity of vitamin C treatment cannot 
be predicted.  
Finally, the authors report that, fol-
lowing DHA uptake, NAD+ depletion 
by PARP activation contributes to the 
inhibition of glycolysis (and potentially 
to the stimulation of oxidative PPP flux). 
The observation that PARP inhibition 
partly rescues vitamin C-treated cells 
may suggest that the toxic effect of DHA 
uptake is not caused by ROS alone, since 
restoring NAD+ levels and glycolysis 
with the PARP inhibitor may actually 
decrease PPP flux and NADPH produc-
tion, and aggravate the redox stress. It 
remains to be demonstrated that PARP 
inhibition indeed restores NAD+ levels 
in vitamin C-treated cells, and how 
this affects the balance between energy 
and redox metabolism. This also raises 
the question whether PARP activity in 
BRCA1/2-deficient tumors produces a 
similar metabolic phenotype via NAD+ 
depletion and whether the use of a PARP 
inhibitor (e.g., olaparib) to treat these 
tumors [10] might restore NAD+ levels 
and counterbalance GAPDH inhibition 
by other oxidative agents. 
In summary, Yun et al. [1] show that, 
in glycolysis-addicted KRAS and BRAF 
driven cancer cells, high-dose vitamin C 
treatment induces cell death via the up-
take and reduction of its oxidized form 
DHA back to vitamin C. DHA reduc-
tion, through scavenging GSH, induces 
oxidative stress, leading to GAPDH 
inactivation, inhibition of glycolysis 
and the subsequent energy crisis and 
cell death. This study further elucidates 
the mechanism by which ROS can in-
duce cell death, and neatly shows how 
vitamin C, an antioxidant, can work as 
a double edged sword. However, further 
work is necessary to determine whether 
there is a therapeutic potential for vita-
min C in cancer patients. 
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Figure 1 Mechanistic overview of proposed vitamin C toxicity in CRCs driven by 
KRAS and BRAF mutations. KRAS and BRAF mutations induce metabolic repro-
gramming by upregulating GLUT1, glucose uptake, and glycolytic flux. Upon vitamin 
C treatment and its extracellular oxidation, DHA (the oxidized form of vitamin C) is 
taken up through GLUT1 and is reduced back to vitamin C in the cells, depleting 
GSH and NADPH. Consequently, an increase in ROS leads to GAPDH oxidation, 
and with it, to a decrease in glycolytic flux. In parallel, ROS-mediated oxidative DNA 
damage induces PARP activation and subsequently, NAD+ levels fall and cause ad-
ditional inhibition of GAPDH and glycolysis, resulting in energy crisis and cell death.
